【貓】評論

病人為59歲男性，過去病史有CADLDL: 200mg/dl, HDL:42mg/dl, TG:180mg/dl<S> 59 y/o male<O>PI: DyslipidemiaPMH: CADAllergy: NDAcurrent medication: unknowncurrent lab data(lipid panel):LDL: 200mg/dl, HDL:42mg/dl, TG:180mg/dl<A>1. Dyslipidemia:clinical ASCVD + not at very high risk註(1 ASCVD event +LDL>100mg/dl; <75 y/o)goal: LDL<70mg/dl, TG:<150mg/dl(ref of LDL Goal: 2022 TW lipid guidelines for high risk pt: CAD, PAD and ischemic stroke)→recommend high-intensity statin tx (eg. Atorvastatin 40-80mg, Rosuvastatin20-40mg)→recommend add Lipitor*(20) #2 qd or Tulip*(40) #1 qd or Crestor*(10) #2 qd註: 以台灣治療指引條件劃定2. Secondary prevention of ACS: (omit)<P>1. Recommend add Lipitor*(20) #2 qd or Tulip*(40) #1 qd or Crestor*(10) #2 qd for dyslipidemia with CAD.Please recheck lipid panel 4 to 12 weeks after initiating therapy and every 3 to 12 months thereafter.(If 2 consecutive LDL levels are <40 mg/dL, consider decreasing the dose.)Consider add Ezetimibe if is still unable to acheive optimal LDL goal.Routine monitoring of hepatic function and CK levels is not recommend unless pt has signs of suggestive of hepatic or muscle injury. Monitor closely for myopathy/rhabdomyolysis.故選(B)作為降血脂首選用藥，且Atorvastatin的劑量必須為40-80mg，作為高強度statin txcf:Atorvastatin 10-20mg為中強度statin tx===2022 TW lipid guideline:CAD:1. LDL goal: <70mg/dl2. LDL goal at very high risk*: <55mg/dl*diabetes, those with recent MI (<12 months), 2 prior MIs, multivessel CAD, or concomitant PAD (including extremity or carotid artery)

【Panbosin】評論

有冠狀動脈心臟疾病，最近LDL 200 mg/dL、HDL 42 mg/dL、TG 180 mg/dLLDL 200 大於正常值100TG也偏高通常會先使用STATIN藥物把LDL降下來

【蛋捲好可愛】評論

血脂肪的標準值：三酸★★★★★★200 ☆☆...

【洪峻澤】評論

補充：LDL計算，沉寂已久的考點，說不定...